Site and Investigator
Hospital Pulau Pinang (Dr Tan Sui Keat)
Hospital Queen Elizabeth (Dr Lily Wong Lee Lee)
University Malaya Medical Centre – UMMC (Dr Bee Ping Chong)
Subang Jaya Medical Centre (Dr Ng Soo Chin)
Title
A Phase 3 Randomized Study Comparing Teclistamab Monotherapy versus Pomalidomide, Bortezomib, Dexamethasone (PVd) or Carfilzomib, Dexamethasone (Kd) in Participants with Relapsed or Refractory Multiple Myeloma who have Received 1 to 3 Prior Lines of Therapy, Including an Anti-CD38 Monoclonal Antibody and Lenalidomide (MajesTEC-9)
Key Criteria of the Study
Aged 18 or older
Have recurrent or treatment-resistant multiple myeloma
Have had 1-3 prior treatments for multiple myeloma and at least 2 consecutive cycles of Daratumumab (anti CD38 monoclonal antibody) and Lenalidomide in prior lines
Clinicaltrials.gov Identifier
NCT05572515
NMRR ID
NMRRID-22-02312-BOH
Further details
Registration
Registration Via link: Clinicalresearchmajestec9
Contact Number: +603 7931 5566 (114/115)
To find out more on how we can help,
+63-2698 7300 | contact@cancer.org.my
